Home Industries Market Insights About Us Publisher Contact us

Pelvic Inflammatory Disease (PID) Market Growth, Trends and Forecast to 2028 – Global Analysis By Type (Subacute, Chronic, Sexually Transmitted and Others), By Drug Class (Macrolides, Tetracycline, Beta-lactam, Nitroimidazoles and Others), By Mode of Administration (Oral, Intramuscular and Intravenous), By End User (Hospitals, Homecare, Specialty Clinics and Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others) and By Geography

Categories: Life Science   |   Formate :

MARKET DEFINITION

Pelvic inflammatory disease (PID) is a female reproductive organ illness. The pelvis, which is positioned in the lower abdomen, contains the fallopian tubes, ovaries, cervix, and uterus. PID can be caused by a variety of bacteria, including the same germs that cause sexually transmitted diseases (STIs) gonorrhea and chlamydia. Bacteria frequently enter the vagina and create an infection. This infection has the potential to spread to the pelvic organs over time. If the infection spreads to the blood, PID can become highly severe, even fatal. Mild to moderate pain can be caused by pelvic inflammatory disease.

MARKET DYNAMICS

Growing female awareness of pelvic inflammatory disease is driving the diagnosis rate, resulting in a greater proportion of women getting treated for the condition. Growth of the pelvic inflammatory disease therapeutics market is the increase in the number of women in their reproductive phase, when the risk of getting pelvic inflammatory disease is rising globally. Misdiagnosis and the use of preventative treatments, on the other hand, may stymie the market growth of pelvic inflammatory disease therapies. The increased delivery of PID therapies through retail pharmacies, as well as the increase in the number of retail pharmacies in developed nations, provide prospects for market expansion.

REPORT SCOPE

The report titled “Global Pelvic Inflammatory Disease (PID) Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Pelvic Inflammatory Disease (PID) market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Pelvic Inflammatory Disease (PID) market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Pelvic Inflammatory Disease (PID) Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION

The Global Pelvic Inflammatory Disease (PID) Market is segmented based on type, drug class, mode of administration, end user, distribution channel, and region. Based on type, the market has been segmented into Subacute, Chronic, Sexually Transmitted and Others, whereas based on drug class, the market comprises Macrolides, Tetracycline, Beta-lactam, Nitroimidazoles and Others. Based on the mode of administration, the market has been segmented into Oral, Intramuscular and Intravenous, whereas, the end user segmentation includes Hospitals, Homecare, Specialty Clinics and Others. Based on distribution channel Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Pelvic Inflammatory Disease (PID) market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Pelvic Inflammatory Disease (PID) market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Pelvic Inflammatory Disease (PID) market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Pelvic Inflammatory Disease (PID) industry in the past three years.

Key players in the Global Pelvic Inflammatory Disease (PID) Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

  • Mayne Pharma Group Limited
  • AstraZeneca
  • Pfizer Inc
  • Johnson and Johnson services Inc
  • Hoffmann-La Roche Ltd
  • Janssen Pharmaceuticals
  • Merck & Co.
  • Sanofi,
  • Mylan N.V.
  • Bristol Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd

COVID-19 IMPACT ANALYSIS ON GLOBAL PELVIC INFLAMMATORY DISEASE (PID) MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

Report Attribute/Metric

Details

Market Size

In USD Million

CAGR

In % (2022-2028)

Base Year

2021

Forecast Period

2022 – 2028

Historical Data

2017 to 2021

Forecast Unit

Value (US$ Mn)

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Factors and Trends

Geographies Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Key Players Analyzed

Mayne Pharma Group Limited, AstraZeneca, Pfizer Inc, Johnson and Johnson services Inc, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Merck & Co., Sanofi, Mylan N.V., Bristol Myers Squibb Company and Teva Pharmaceutical Industries Ltd

Customization & Pricing

Available on Request (10% Customization is Free)

 

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

  1. What is the current size of the global Pelvic Inflammatory Disease (PID) market?
  2. What will be the growth rate of the market over the forecast period?
  3. Who are the key manufacturers/vendors in the Pelvic Inflammatory Disease (PID) market space?
  4. What are the major market opportunities and market risks faced by the market?
  5. What is the impact of COVID-19 on the market?
  6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
  7. What are the key outcomes of Porter's five forces model?
  8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

  • The report offers comprehensive data on the Pelvic Inflammatory Disease (PID) market elaborating on the current state and future growth prospects both globally and regionally
  • It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
  • The report offers deep-dive insights into each market segment and critical factors responsible for its growth
  • The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
  • The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
  • Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
  • The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 


 
Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
 
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
 
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Type Trends
3.2.2. Drug Class Trends
3.2.3. Mode of Administration Trends
3.2.4. End User Trends
3.2.5. Distribution Channel Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Pelvic Inflammatory Disease (PID) Market
3.6. COVID-19 Impact Assessment in Pelvic Inflammatory Disease (PID) Market
3.6.1. Impact Assessment on Global Pelvic Inflammatory Disease (PID) Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
 
Chapter 4. Global Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
4.1. Global Pelvic Inflammatory Disease (PID) Market Share, By Type, 2017 - 2028 (USD Million)
4.1.1. Subacute
4.1.2. Chronic
4.1.3. Sexually Transmitted
4.1.4. Others
 
Chapter 5. Global Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
5.1. Global Pelvic Inflammatory Disease (PID) Market Share, By Drug Class, 2017 - 2028 (USD Million)
5.1.1. Macrolides
5.1.2. Tetracycline
5.1.3. Beta-lactam
5.1.4. Nitroimidazoles
5.1.5. Others
 
Chapter 6. Global Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
6.1. Global Pelvic Inflammatory Disease (PID) Market Share, By Mode of Administration, 2017 - 2028 (USD Million)
6.1.1. Oral
6.1.2. Intramuscular
6.1.3. Intravenous
 
Chapter 7. Global Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
7.1. Global Pelvic Inflammatory Disease (PID) Market Share, By End User, 2017 - 2028 (USD Million)
7.1.1. Hospitals
7.1.2. Homecare
7.1.3. Specialty Clinics
7.1.4. Others


 
Chapter 8. Global Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.1. Global Pelvic Inflammatory Disease (PID) Market Share, By Distribution Channel, 2017 - 2028 (USD Million)
8.1.1. Hospital Pharmacy
8.1.2. Online Pharmacy
8.1.3. Retail Pharmacy
8.1.4. Others
 
Chapter 9. Global Pelvic Inflammatory Disease (PID) Market Overview, By Geography, 2017 - 2028 (USD Million)
9.1. Global Pelvic Inflammatory Disease (PID) Market Share, By Geography, 2017 - 2028 (USD Million)
9.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)
9.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)
 
Chapter 10. North America Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. North America Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market size and projections, 2017 - 2028 (USD Million)
10.1.2. North America Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
10.1.3. North America Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.1.4. North America Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
10.1.5. North America Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
10.1.6. North America Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2. North America Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. U.S. Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. U.S. Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.1.2. U.S. Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.1.3. U.S. Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
10.2.1.4. U.S. Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.1.5. U.S. Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.2. Canada Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. Canada Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.2.2. Canada Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.2.3. Canada Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
10.2.2.4. Canada Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.2.5. Canada Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.3. Mexico Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Mexico Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
10.2.3.2. Mexico Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.3.3. Mexico Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
10.2.3.4. Mexico Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
10.2.3.5. Mexico Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 11. Europe Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Europe Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market size and projections, 2017 - 2028 (USD Million)
11.1.2. Europe Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.1.3. Europe Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.1.4. Europe Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.1.5. Europe Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.1.6. Europe Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2. Europe Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. Germany Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. Germany Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.1.2. Germany Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.1.3. Germany Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.1.4. Germany Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.1.5. Germany Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.2. France Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. France Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.2.2. France Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.2.3. France Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.2.4. France Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.2.5. France Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.3. UK Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. UK Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.3.2. UK Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.3.3. UK Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.3.4. UK Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.3.5. UK Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.4. Italy Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.4.1. Italy Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.4.2. Italy Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.4.3. Italy Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.4.4. Italy Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.4.5. Italy Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.5. Spain Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.5.1. Spain Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.5.2. Spain Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.5.3. Spain Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.5.4. Spain Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.5.5. Spain Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.6. NORDIC Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.6.1. NORDIC Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.6.2. NORDIC Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.6.3. NORDIC Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.6.4. NORDIC Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.6.5. NORDIC Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.7. Russia and CIS Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.7.1. Russia and CIS Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.7.2. Russia and CIS Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.7.3. Russia and CIS Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.7.4. Russia and CIS Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.7.5. Russia and CIS Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.8. Rest of Europe Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
11.2.8.1. Rest of Europe Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
11.2.8.2. Rest of Europe Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.8.3. Rest of Europe Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
11.2.8.4. Rest of Europe Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
11.2.8.5. Rest of Europe Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 12. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market size and projections, 2017 - 2028 (USD Million)
12.1.2. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.1.3. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.1.4. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.1.5. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.1.6. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2. Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. India Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. India Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.1.2. India Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.1.3. India Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.1.4. India Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.1.5. India Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.2. China Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. China Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.2.2. China Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.2.3. China Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.2.4. China Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.2.5. China Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.3. Japan Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Japan Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.3.2. Japan Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.3.3. Japan Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.3.4. Japan Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.3.5. Japan Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.4. ASEAN Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.4.1. ASEAN Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.4.2. ASEAN Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.4.3. ASEAN Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.4.4. ASEAN Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.4.5. ASEAN Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.5. South Korea Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.5.1. South Korea Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.5.2. South Korea Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.5.3. South Korea Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.5.4. South Korea Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.5.5. South Korea Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.6. Australia Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.6.1. Australia Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.6.2. Australia Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.6.3. Australia Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.6.4. Australia Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.6.5. Australia Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.7. Rest of Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
12.2.7.1. Rest of Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
12.2.7.2. Rest of Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.7.3. Rest of Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
12.2.7.4. Rest of Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
12.2.7.5. Rest of Asia Pacific Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 13. South America Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
13.1. South America Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
13.1.1. Market size and projections, 2017 - 2028 (USD Million)
13.1.2. South America Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
13.1.3. South America Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.1.4. South America Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
13.1.5. South America Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
13.1.6. South America Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
13.2. South America Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
13.2.1. Brazil Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
13.2.1.1. Brazil Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
13.2.1.2. Brazil Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.2.1.3. Brazil Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
13.2.1.4. Brazil Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
13.2.1.5. Brazil Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
13.2.2. Argentina Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
13.2.2.1. Argentina Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
13.2.2.2. Argentina Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.2.2.3. Argentina Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
13.2.2.4. Argentina Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
13.2.2.5. Argentina Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
13.2.3. Rest of South America Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
13.2.3.1. Rest of South America Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
13.2.3.2. Rest of South America Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
13.2.3.3. Rest of South America Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
13.2.3.4. Rest of South America Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
13.2.3.5. Rest of South America Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 14. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
14.1. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
14.1.1. Market size and projections, 2017 - 2028 (USD Million)
14.1.2. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
14.1.3. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
14.1.4. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
14.1.5. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
14.1.6. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
14.2. Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Countries, 2017 - 2028 (USD Million)
14.2.1. GCC Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
14.2.1.1. GCC Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
14.2.1.2. GCC Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
14.2.1.3. GCC Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
14.2.1.4. GCC Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
14.2.1.5. GCC Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
14.2.2. South Africa Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
14.2.2.1. South Africa Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
14.2.2.2. South Africa Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
14.2.2.3. South Africa Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
14.2.2.4. South Africa Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
14.2.2.5. South Africa Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
14.2.3. Rest of Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, 2017 - 2028 (USD Million)
14.2.3.1. Rest of Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Type, 2017 - 2028 (USD Million)
14.2.3.2. Rest of Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Drug Class, 2017 - 2028 (USD Million)
14.2.3.3. Rest of Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Mode of Administration, 2017 - 2028 (USD Million)
14.2.3.4. Rest of Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By End User, 2017 - 2028 (USD Million)
14.2.3.5. Rest of Middle East & Africa Pelvic Inflammatory Disease (PID) Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
 
Chapter 15. Competitive Landscape
15.1. Competitive Environment, 2021
15.2. Strategic Framework
15.2.1. Partnership/Collaborations/Agreement
15.2.2. Expansion
15.2.3. Mergers & Acquisitions
15.2.4. New Product Development
 
Chapter 16. Key Vendor Analysis
16.1. Mayne Pharma Group Limited
16.1.1. Business Overview
16.1.2. Product Benchmarking
16.1.3. Financial Data
16.1.4. Strategic Overview
16.1.5. Key Developments
16.1.6. SWOT Analysis
16.2. AstraZeneca
16.2.1. Business Overview
16.2.2. Product Benchmarking
16.2.3. Financial Data
16.2.4. Strategic Overview
16.2.5. Key Developments
16.2.6. SWOT Analysis
16.3. Pfizer Inc
16.3.1. Business Overview
16.3.2. Product Benchmarking
16.3.3. Financial Data
16.3.4. Strategic Overview
16.3.5. Key Developments
16.3.6. SWOT Analysis
16.4. Johnson and Johnson services Inc
16.4.1. Business Overview
16.4.2. Product Benchmarking
16.4.3. Financial Data
16.4.4. Strategic Overview
16.4.5. Key Developments
16.4.6. SWOT Analysis
16.5. F. Hoffmann-La Roche Ltd
16.5.1. Business Overview
16.5.2. Product Benchmarking
16.5.3. Financial Data
16.5.4. Strategic Overview
16.5.5. Key Developments
16.5.6. SWOT Analysis

16.6. Janssen Pharmaceuticals
16.6.1. Business Overview
16.6.2. Product Benchmarking
16.6.3. Financial Data
16.6.4. Strategic Overview
16.6.5. Key Developments
16.6.6. SWOT Analysis
16.7. Merck & Co.
16.7.1. Business Overview
16.7.2. Product Benchmarking
16.7.3. Financial Data
16.7.4. Strategic Overview
16.7.5. Key Developments
16.7.6. SWOT Analysis
16.8. Sanofi,
16.8.1. Business Overview
16.8.2. Product Benchmarking
16.8.3. Financial Data
16.8.4. Strategic Overview
16.8.5. Key Developments
16.8.6. SWOT Analysis
16.9. Mylan N.V.
16.9.1. Business Overview
16.9.2. Product Benchmarking
16.9.3. Financial Data
16.9.4. Strategic Overview
16.9.5. Key Developments
16.9.6. SWOT Analysis
16.10. Bristol Myers Squibb Company
16.10.1. Business Overview
16.10.2. Product Benchmarking
16.10.3. Financial Data
16.10.4. Strategic Overview
16.10.5. Key Developments
16.10.6. SWOT Analysis
16.11. Teva Pharmaceutical Industries Ltd
16.11.1. Business Overview
16.11.2. Product Benchmarking
16.11.3. Financial Data
16.11.4. Strategic Overview
16.11.5. Key Developments
16.11.6. SWOT Analysis
 
Chapter 17. Future Outlook of the Market

 

Request For Methodology

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

Request For List Of Tables

To receive a sample copy of this report, please complete the form below

Kindly share your specific requirement (if any)

FAQ

Choose License Type

Single User

US$ 3500

Multi User

US$ 5250

Corporate User

US$ 7000

Personalize this Research

  • Market Size and Share from 2016 - 2027
  • Expected Market Growth Until 2027
  • COVID-19 Impact assessment on the market
  • Market Dynamics and Impact Analysis
  • Segment and region that will drive or lead the market growth and why
  • Industry activity comprising Mergers, Acquisitions, Expansion, etc.
  • Comprehensive Mapping of the Competitive Landscape
  • In-depth analysis of key sustainability strategies adopted by market players
  • Global and regional market trends – Current and Future
  • Value Chain Analysis
  • Porters Five Forces Analysis
  • Historical and Current Product Pricing
  • Country Cross-Segment Analysis
  • Company Profiling
  • Player Comparison Matrix

Life Science Clients

Pelvic Inflammatory Disease (PID) Market Growth, T...

RD Code : HP22